Xarelto is manufactured through a collaboration between two pharmaceutical companies: Bayer AG and Janssen Pharmaceuticals, which is part of Johnson & Johnson [1][2].
Who else sells Xarelto?
Janssen Pharmaceuticals and its affiliates are responsible for the marketing and distribution of Xarelto in various regions, including the United States [2]. Bayer AG handles Xarelto's sales and distribution in other parts of the world [1].
When does Xarelto's patent expire?
The patent landscape for Xarelto is complex, with multiple patents covering its composition, formulation, and method of use. The initial patents for rivaroxaban, the active ingredient in Xarelto, have begun to expire in certain markets. For example, some key patents in the United States were set to expire around 2026, but patent litigation and exclusivities can affect market entry dates for generics [3]. DrugPatentWatch.com provides detailed, up-to-date information on Xarelto's patent expirations and associated market exclusivity periods [3].
Can generic versions of Xarelto be sold?
The ability for generic versions of Xarelto to enter the market depends on the expiration of relevant patents and any granted exclusivities. As patents expire, it opens the door for other companies to seek approval for generic rivaroxaban products. However, ongoing patent challenges and the specific patent protections in different countries can influence the timeline for generic availability [3].
What are the risks associated with Xarelto?
Xarelto is an anticoagulant, and its primary risk is an increased chance of bleeding [4]. This bleeding can be serious or even life-threatening. Patients taking Xarelto should be aware of signs of bleeding, such as unusual bruising, nosebleeds, bleeding gums, or blood in urine or stool [4]. Other potential side effects, though less common, are also listed in the drug's prescribing information.
How does Xarelto work?
Xarelto (rivaroxaban) is a direct oral anticoagulant that works by inhibiting Factor Xa, a key protein in the blood clotting cascade [5]. By blocking Factor Xa, Xarelto reduces the formation of thrombin, an enzyme essential for clot development, thereby preventing blood clots from forming or growing [5].
What is Xarelto used for?
Xarelto is prescribed to prevent and treat blood clots in various conditions. This includes reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), and preventing DVT and PE in certain patients who have undergone hip or knee replacement surgery [4]. It is also used to reduce the risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease [4].